Companies

Lupin launches generic GERD drug in US

PTI New Delhi | Updated on March 12, 2018 Published on November 11, 2013

Drug major Lupin has launched a generic version of Japan-headquartered Eisai Inc’s Aciphex delayed-release tablets, used to treat gastroesophageal reflux disease, in the US market.

The company’s US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market, after having received approval from the US Food and Drug Administration to market it, according to a statement by Lupin.

Lupin’s product is generic equivalent of Eisai Inc’s Aciphex delayed-release tablets, 20 mg, and it is indicated for the treatment of gastroesophageal reflux disease (GERD), it added.

According to IMS MAT June 2013 sales data, Aciphex delayed-release tablets, 20 mg, had annual US sales of around $864.3 million.

Shares of Lupin were trading at Rs 886.30 a piece on the BSE in the late afternoon trade, up 0.3 per cent from their previous close.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on November 11, 2013
null
This article is closed for comments.
Please Email the Editor